Cyclic phosphatidic acid derivative is a novel drug candidate for multiple sclerosis

Abstract

Event Abstract Back to Event Cyclic phosphatidic acid derivative is a novel drug candidate for multiple sclerosis Keisuke Yoshikawa1*, Shinji Yamamoto1, Mari Gotoh2, Takabumi Shimizu2, Miho Hashimoto1, Kota Yamashina1, Masahiko Suzuki1, Kei Maruyama1 and Kimiko Murakami-Murofushi2 1 Saitama Medical University, Department of Pharmacology, Faculty of Medicine, Japan 2 Ochanomizu University, Endowed Research Division of Human Welfare Sciences, Japan Multiple sclerosis is a chronic demyelinating disease of the central nervous system leading to progressive cognitive and motor dysfunction, which is characterized by neuroinflammation, demyelination, astrogliosis, loss of oligodendrocytes, and axonal pathologies. Cyclic phosphatidic acid (cPA) is a naturally occurring phospholipid mediator, is present in serum and brain, and elicits a neurotrophin-like action and protects hippocampal neurons from ischemia-induced delayed neuronal death. We previously reported that cPA suppressed demyelination and motor dysfunction in the cuprizone (CPZ)-induced Multiple sclerosis model. In this study, we investigated the effects of cPA derivative on the CPZ model. cPA derivative potently suppressed CPZ-induced demyelination, neuroinflammation, and motor dysfunction. These data indicate that cPA derivative may be a useful treatment to reduce the extent of demyelination and the severity of motor dysfunction in multiple sclerosis. Keywords: Hippocampus, Multiple Sclerosis, Neuroinflammation, demyelination, Motor dysfunction Conference: 14th Meeting of the Asian-Pacific Society for Neurochemistry, Kuala Lumpur, Malaysia, 27 Aug - 30 Aug, 2016. Presentation Type: Free Paper Session 1: Novel Therapy for Brain Disorders Topic: 14th Meeting of the Asian-Pacific Society for Neurochemistry Citation: Yoshikawa K, Yamamoto S, Gotoh M, Shimizu T, Hashimoto M, Yamashina K, Suzuki M, Maruyama K and Murakami-Murofushi K (2016). Cyclic phosphatidic acid derivative is a novel drug candidate for multiple sclerosis. Conference Abstract: 14th Meeting of the Asian-Pacific Society for Neurochemistry. doi: 10.3389/conf.fncel.2016.36.00097 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 04 Aug 2016; Published Online: 11 Aug 2016. * Correspondence: Dr. Keisuke Yoshikawa, Saitama Medical University, Department of Pharmacology, Faculty of Medicine, Iruma, Saitama, Japan, kykeisukey04@gmail.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Keisuke Yoshikawa Shinji Yamamoto Mari Gotoh Takabumi Shimizu Miho Hashimoto Kota Yamashina Masahiko Suzuki Kei Maruyama Kimiko Murakami-Murofushi Google Keisuke Yoshikawa Shinji Yamamoto Mari Gotoh Takabumi Shimizu Miho Hashimoto Kota Yamashina Masahiko Suzuki Kei Maruyama Kimiko Murakami-Murofushi Google Scholar Keisuke Yoshikawa Shinji Yamamoto Mari Gotoh Takabumi Shimizu Miho Hashimoto Kota Yamashina Masahiko Suzuki Kei Maruyama Kimiko Murakami-Murofushi PubMed Keisuke Yoshikawa Shinji Yamamoto Mari Gotoh Takabumi Shimizu Miho Hashimoto Kota Yamashina Masahiko Suzuki Kei Maruyama Kimiko Murakami-Murofushi Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.